https://www.humanexa.io/ 2026-06-06T02:03:41.987Z daily 1 https://www.humanexa.io/pricing 2026-06-06T02:03:41.987Z weekly 0.95 https://www.humanexa.io/insights 2026-06-06T02:03:41.987Z weekly 0.9 https://www.humanexa.io/signals 2026-06-06T02:03:41.987Z weekly 0.9 https://www.humanexa.io/regulatory 2026-06-06T02:03:41.987Z weekly 0.9 https://www.humanexa.io/strategy 2026-06-06T02:03:41.987Z weekly 0.9 https://www.humanexa.io/simulations 2026-06-06T02:03:41.987Z weekly 0.9 https://www.humanexa.io/workspace 2026-06-06T02:03:41.987Z weekly 0.9 https://www.humanexa.io/welcome 2026-06-06T02:03:41.987Z weekly 0.9 https://www.humanexa.io/privacy 2026-06-06T02:03:41.987Z yearly 0.3 https://www.humanexa.io/terms 2026-06-06T02:03:41.987Z yearly 0.3 https://www.humanexa.io/insights/emerging-anesthetic-techniques-and-opioid-sparing-strategies-in-pain-management 2026-06-06T01:07:30.174Z weekly 0.85 https://www.humanexa.io/insights/navigating-new-fda-guidance-on-pregnancy-safety-studies-in-drug-development 2026-06-03T01:14:21.514Z weekly 0.85 https://www.humanexa.io/insights/breztris-unique-positioning-as-first-triple-therapy-in-asthma-market 2026-06-03T01:14:21.674Z weekly 0.85 https://www.humanexa.io/insights/astrazenecas-baxfendy-approval-a-strategic-shift-in-hypertension-treatment 2026-06-03T01:14:21.834Z weekly 0.85 https://www.humanexa.io/insights/enhertus-potential-eu-approval-could-transform-her2-treatment-landscape 2026-06-05T20:48:17.521Z weekly 0.85 https://www.humanexa.io/insights/tozorakimabs-phase-iii-success-positions-it-as-a-leader-in-copd-treatment 2026-06-06T01:07:30.145Z weekly 0.85 https://www.humanexa.io/insights/positive-phase-iii-results-for-efzimfotase-alfa-reshape-hypophosphatasia-landsca 2026-06-03T01:14:22.460Z weekly 0.85 https://www.humanexa.io/insights/imfinzi-and-imjudos-pfs-improvement-signals-competitive-shift-in-liver-cancer 2026-06-05T13:59:00.812Z weekly 0.85 https://www.humanexa.io/insights/emerging-therapeutics-in-copd-tozorakimab-and-nmes-trials-signal-strategic-shift 2026-06-06T01:07:30.292Z weekly 0.85 https://www.humanexa.io/insights/emerging-combination-therapies-and-targeted-approaches-in-liver-cancer-treatment 2026-06-05T13:59:01.000Z weekly 0.85 https://www.humanexa.io/signals/fda-accepts-supplement-application-for-tyvaso-treprostinil 2026-06-06T00:00:51.990Z weekly 0.8 https://www.humanexa.io/signals/fda-submission-for-dapagliflozin-by-jiangsu-hansoh-pharma 2026-06-06T00:00:40.603Z weekly 0.8 https://www.humanexa.io/signals/comparative-study-of-spsipb-vs-thoracic-paravertebral-block-for-opioid-reduction 2026-06-02T03:09:28.046Z weekly 0.8 https://www.humanexa.io/signals/pilot-study-on-geniculate-artery-embolization-for-knee-osteoarthritis-initiated 2026-06-02T03:09:23.745Z weekly 0.8 https://www.humanexa.io/signals/imfinziimjudo-shows-significant-pfs-improvement-in-early-liver-cancer-trial 2026-06-02T03:09:20.953Z weekly 0.8 https://www.humanexa.io/signals/efzimfotase-alfa-shows-positive-phase-iii-results-in-hypophosphatasia 2026-06-02T03:09:15.835Z weekly 0.8 https://www.humanexa.io/signals/trial-on-pulmonary-artery-catheters-in-cardiac-surgery-aims-to-compare-recovery- 2026-06-02T03:01:35.313Z weekly 0.8 https://www.humanexa.io/signals/tapur-study-evaluates-targeted-therapies-in-advanced-cancer-with-genomic-variant 2026-06-02T03:01:32.508Z weekly 0.8 https://www.humanexa.io/signals/tozorakimab-achieves-primary-endpoints-in-phase-iii-trials-for-copd 2026-06-02T03:01:29.578Z weekly 0.8 https://www.humanexa.io/signals/enhertu-recommended-for-eu-approval-in-her2-metastatic-solid-tumours 2026-06-02T03:01:25.861Z weekly 0.8 https://www.humanexa.io/signals/zhuochuming-trial-evaluates-3te-vs-3prn-in-diabetic-macular-edema 2026-06-01T19:50:47.438Z weekly 0.8 https://www.humanexa.io/signals/study-on-nmes-for-functional-recovery-in-copd-and-pneumonia-patients 2026-06-01T19:50:43.736Z weekly 0.8 https://www.humanexa.io/signals/fda-issues-guidance-on-postapproval-pregnancy-safety-studies 2026-06-01T19:50:38.722Z weekly 0.8 https://www.humanexa.io/signals/astrazenecas-baxfendy-receives-us-approval-for-hypertension-as-first-in-class-tr 2026-06-01T19:50:35.739Z weekly 0.8 https://www.humanexa.io/signals/breztri-gains-us-approval-as-first-triple-therapy-for-asthma 2026-06-01T19:50:32.737Z weekly 0.8